INTERVENTION 1:	Intervention	0
Ramucirumab and Docetaxel Combination	Intervention	1
Docetaxel: Docetaxel administered by intravenous infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.	Intervention	2
meter	UO:0000008	96-101
Ramucirumab: Ramucirumab administered as an intravenous infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.	Intervention	3
Inclusion Criteria:	Eligibility	0
The participant is Japanese	Eligibility	1
The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1	Eligibility	2
group	CHEBI:24433	52-57
The participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is now metastatic or locally-recurrent and inoperable with curative intent	Eligibility	3
breast adenocarcinoma	DOID:3458	82-103
The participant has measurable and/or non-measurable disease	Eligibility	4
disease	DOID:4,OGMS:0000031	53-60
The participants' primary and/or metastatic tumor is Human Epidermal Growth Factor Receptor 2 (HER2) negative	Eligibility	5
growth factor	BAO:0002024	69-82
receptor	BAO:0000281	83-91
The participant received neo adjuvant or adjuvant taxane therapy  6 months prior to the study	Eligibility	6
adjuvant	CHEBI:60809	29-37
adjuvant	CHEBI:60809	41-49
taxane	CHEBI:36064	50-56
The participant received neo adjuvant or adjuvant biologic therapy  6 weeks prior to the study	Eligibility	7
adjuvant	CHEBI:60809	29-37
adjuvant	CHEBI:60809	41-49
The participant completed all prior radiotherapy  3 weeks prior to the study registration date	Eligibility	8
radiotherapy	OAE:0000235	36-48
The participant received prior hormonal therapy for breast cancer in the neo adjuvant, adjuvant,and/or the metastatic setting  2 weeks prior to the study registration date	Eligibility	9
breast cancer	DOID:1612	52-65
adjuvant	CHEBI:60809	77-85
adjuvant	CHEBI:60809	87-95
The participant's left ventricular ejection fraction (LVEF) is within normal ranges	Eligibility	10
left	HP:0012835	18-22
ejection fraction	CMO:0000180	35-52
The participant has adequate hematologic, hepatic, and coagulation function.	Eligibility	11
coagulation	GO:0050817	55-66
function	BAO:0003117,BFO:0000034	67-75
Eligible participants of reproductive potential agree to use adequate contraceptive methods (hormonal or barrier methods) during the study period and for 12 weeks after the last dose of study medication	Eligibility	12
Exclusion Criteria:	Eligibility	13
The participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. Participants with previous treatment of malignancy is eligible, provided that she has been disease free for >3 years	Eligibility	14
active	PATO:0002354	33-39
breast adenocarcinoma	DOID:3458	62-83
skin cancer	DOID:4159	121-132
carcinoma	HP:0030731,DOID:305	74-83
carcinoma	HP:0030731,DOID:305	156-165
neoplasm	HP:0002664,DOID:14566	177-185
disease	DOID:4,OGMS:0000031	278-285
The participant has a known sensitivity to docetaxel	Eligibility	15
The participant has a known sensitivity to agents of similar biologic composition as ramucirumab	Eligibility	16
The participant has a history of chronic diarrheal disease within 6 months prior to the study registration date	Eligibility	17
history	BFO:0000182	22-29
chronic	HP:0011010	33-40
disease	DOID:4,OGMS:0000031	51-58
The participant has received irradiation to a major bone marrow area within 30 days prior to the study registration date	Eligibility	18
bone marrow	UBERON:0002371	52-63
area	PATO:0001323	64-68
The participant has received any experimental agents within 4 weeks prior to the study registration date	Eligibility	19
The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders	Eligibility	20
history	BFO:0000182	22-29
The participant has Grade 3-4 bleeding within 3 months prior to the study registration date	Eligibility	21
The participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy	Eligibility	22
active	PATO:0002354	34-40
The participant has uncontrolled hypertension, symptomatic congestive heart failure, psychiatric illness, or any other serious uncontrolled medical disorders	Eligibility	23
hypertension	HP:0000822,DOID:10763	33-45
congestive heart failure	HP:0001635,DOID:6000	59-83
The participant has brain metastases	Eligibility	24
brain	UBERON:0000955	20-25
The participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome related illness	Eligibility	25
immunodeficiency	HP:0002721	32-48
immunodeficiency	HP:0002721	77-93
virus	BAO:0000232	49-54
acquired immunodeficiency syndrome	DOID:635	68-102
The participant is pregnant or lactating	Eligibility	26
The participant has not fully recovered from effects of prior chemotherapy	Eligibility	27
The participant has undergone major surgery within 28 days prior to the study registration date	Eligibility	28
surgery	OAE:0000067	36-43
Outcome Measurement:	Results	0
Number of Participants With Adverse Events	Results	1
Number participants with drug related dose-limiting toxicities (DLT) during Cycle 1; ramucirumab related: treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or higher TEAE, or TEAE leading to discontinuation or ramucirumab dose modification. DLT=G4 neutropenia >7days; G 3 neutropenia with fever 38.5Â°C requiring IV antibiotics or bacteriemia or sepsis; G4 thrombocytopenia; G 3 thrombocytopenia with bleeding requiring platelets; G  3 prothrombin time and/or partial thromboplastin time in absence of anticoagulants; G  2 hyperbilirubinemia 5 days; QTc >500 milliseconds (ms) or increase 100 ms or arrhythmia; G  4 or uncontrollable hypertension; G  3 nonhematologic toxicity (excluding G3: hypersensitivity, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea without loperamide therapy, nausea/vomiting without antiemetics, transient G3/4 elevation of aminotransferases); treatment delay >2 weeks due to toxicity.	Results	2
drug	CHEBI:23888	25-29
neutropenia	HP:0001875,DOID:1227	278-289
neutropenia	HP:0001875,DOID:1227	302-313
fever	HP:0001945	319-324
sepsis	HP:0100806	375-381
thrombocytopenia	HP:0001873,DOID:1588	386-402
thrombocytopenia	HP:0001873,DOID:1588	408-424
prothrombin time	CMO:0000211	465-481
time	PATO:0000165	477-481
time	PATO:0000165	512-516
hyperbilirubinemia	HP:0002904,DOID:2741	552-570
increase	BAO:0001251	609-617
arrhythmia	HP:0011675	628-638
hypertension	HP:0000822,DOID:10763	663-675
hypersensitivity	GO:0002524,DOID:1205	721-737
diarrhea	HP:0002014,DOID:13250	802-810
loperamide	CHEBI:6532	819-829
transient	HP:0025153	876-885
Time frame: Baseline up to data cut off (approximately 48.3 weeks)	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Ramucirumab and Docetaxel Combination	Results	5
Arm/Group Description: Docetaxel: Docetaxel administered by intravenous infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.	Results	6
meter	UO:0000008	119-124
Ramucirumab: Ramucirumab administered as an intravenous infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.	Results	7
Overall Number of Participants Analyzed: 7	Results	8
Measure Type: Number	Results	9
Unit of Measure: participants  Dose Limiting Toxicity (DLT) during Cycle 1: 2	Results	10
TEAE related to ramucirumab: 7	Results	11
SAE related to ramucirumab: 4	Results	12
TEAE of Grade   3 related to ramucirumab: 6	Results	13
TEAE resulting in ramucirumab discontinuation: 3	Results	14
TEAE with ramucirumab dose modification/delay: 5	Results	15
Adverse Events 1:	Adverse Events	0
Total: 7/7 (100.00%)	Adverse Events	1
Febrile neutropenia 3/7 (42.86%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Cardiac failure 1/7 (14.29%)	Adverse Events	3
Neutrophil count decreased 1/7 (14.29%)	Adverse Events	4
Muscular weakness 1/7 (14.29%)	Adverse Events	5
Epistaxis 1/7 (14.29%)	Adverse Events	6
epistaxis	HP:0000421	0-9
Interstitial lung disease 1/7 (14.29%)	Adverse Events	7
interstitial lung disease	DOID:3082	0-25
Pleural effusion 2/7 (28.57%)	Adverse Events	8
pleural effusion	HP:0002202	0-16
